Shionogi’s COVID-19 treatment Xocova was found to reduce the risk of developing at least one of the symptoms of long COVID-19, the Osaka-based pharmaceutical company said Wednesday.
Shionogi, which has yet to publish its results in a journal, presented the data at an academic conference held in the U.S. this week.
The data was obtained through a follow-up study of patients with mild or moderate COVID-19 registered in a clinical trial for the approval of Xocova as a treatment for the virus. The drug received emergency approval in Japan in November as the third oral treatment available in the country and the first to be developed domestically.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.